Month: August 2023

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA...

Preliminary Clinical Trial Presentation for Stem Cell and Dementia Held by Beauty-Stem Biomedical and Tzu Chi Hospital in Los Angeles, CA

First stem cell clinical trial landscape is revolutionized by Beauty-Stem Biomedical and Taiwan Tzu Chi Hospital, unveiling the progress of...

Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced the successful...

Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials

MB22001 has been manufactured ready for use in Phase 2 clinical trialsWorld first take-home approvals for psychedelic microdosingVANCOUVER, BC /...

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...

Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B

Poster presentation at National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 highlights effective prophylaxis, control of bleeding episodes, and consistent...

Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variantUpdated...

72-Provider FQHC Implements eClinicalWorks Population Health Solutions for Improved Screening and Compliance

eClinicalWorks population health solutions streamline patient data for Connecticut Institute for Communities, Inc.WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR,...

error: Content is protected !!